Briciclib

Drug Profile

Briciclib

Alternative Names: Briciclib sodium; ON-013105; ON-014185

Latest Information Update: 16 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Temple University
  • Developer Onconova Therapeutics
  • Class Antineoplastics; Phenols; Phenyl ethers; Small molecules; Sulfones
  • Mechanism of Action Cyclin D1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • No development reported Lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 09 Nov 2017 Phase I development in Solid-tumours (Metastatic disease) is ongoing in USA (IV, Infusion) (Onconova pipeline, November 2017)
  • 21 Sep 2017 Cellectar Biosciences and Onconova Therapeutics enter into a collaboration to develop phospholipid drug conjugates, including briciclib, for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top